Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD PharmaTimesEarly safety and efficacy signals support move into repeatdose phase 2a trialOphthalmologyRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) PharmaTimes Early safety and efficacy signals support move into repeatdose phase 2a trial Ophthalmology Read full story Post navigation Previous: Lilly, Gilead lead pharma’s M&A boomNext: BMS’ Sotyktu secures EC approval for psoriatic arthritis Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
